EUVIMEDEUVIMED entdecken
Open Access

Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy

Ryotaro Onoue, Hiroyuki Watanabe iD, Masahiro Ono iD

ACS Pharmacology & Translational Science · 10.05.2024 · 7 (5) · 1395-1403

DOI: 10.1021/acsptsci.4c00035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 29.04.2024. Verfasst von Ryotaro Onoue und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fusion Oriented REsearch for disruptive Science and Technology.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Auger electron therapy and photodynamic therapy (PDT) have attracted attention as powerful anticancer modalities. Herein, we report the development of novel bimodal agents for Auger electron therapy and PDT, and their application to combination therapy. [125I]NBH-1/NBH-1 and [125I]NBH-2/NBH-2, composing Hoechst and iodostyryl-BODIPY, were synthesized and evaluated regarding their usefulness as bimodal agents. [125I]NBH-1 showed significantly higher nuclear uptake than [125I]NBH-2 and radioactivity-dependent cytotoxicity induced by Auger electrons. In addition, NBH-1 exhibited photoinduced cytotoxicity. Combination therapy using [125I]NBH-1 and NBH-1 with light irradiation induced a superior cytotoxicity to these treatments alone. In tumor-bearing mice injected with NBH-1 or [125I]NBH-1/NBH-1 under light irradiation, significant tumor growth inhibition was observed compared with that of the control group. Especially, [125I]NBH-1/NBH-1 under light irradiation showed the strongest therapeutic effects among all treatments. These results suggest that [125I]NBH-1/NBH-1 is a potent bimodal agent for Auger therapy and PDT and that combination therapy using [125I]NBH-1 and NBH-1 shows enhanced therapeutic efficacy.

Autor:innen und Institutionen

  • Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.

ORCID-Profile: Hiroyuki Watanabe, Masahiro Ono

Förderung

  • Fusion Oriented REsearch for disruptive Science and Technology

Zitieren

APA

Onoue, R., Watanabe, H., & Ono, M. (2024). Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy. ACS Pharmacology & Translational Science, 7(5), 1395-1403. https://doi.org/10.1021/acsptsci.4c00035

Vancouver

Onoue R, Watanabe H, Ono M. Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy. ACS Pharmacology & Translational Science. 2024;7(5):1395-1403. doi:10.1021/acsptsci.4c00035

BibTeX
@article{Onoue2024,
  author = {Onoue, Ryotaro and Watanabe, Hiroyuki and Ono, Masahiro},
  title = {Development of Novel Bimodal Agents Based on Near-Infrared BODIPY-Conjugated Hoechst Derivatives for Combined Use in Auger Electron and Photodynamic Cancer Therapy},
  journal = {ACS Pharmacology & Translational Science},
  year = {2024},
  volume = {7},
  number = {5},
  pages = {1395--1403},
  doi = {10.1021/acsptsci.4c00035}
}
Kostenlos starten →